Citations

Clear

1446 citation(s) found for "Howard, F".

Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures
Joie, Renaud La , Ayakta, Nagehan , Borys, Ewa, Boxer, Adam L. , DeCarli, Charles , Doré, Vincent , Grinberg, Lea T. , Huang, Eric J. , Hwang, Ji‐Hye , Ikonomović, Miloš D. , Jack, Clifford R. , Jagust, William J. , Jin, Lee‐Way, Klunk, William E. , Kofler, Julia , Lesman‐Segev, Orit H. , Lockhart, Samuel N. , Lowe, Val J. , Masters, Colin L. , Mathis, Chester A. , McLean, Catriona , Miller, Bruce L. , Mungas, Daniel, O’Neil, James P. , Olichney, John , Parisi, Joseph E., Petersen, Ronald C. , Rosen, Howard J. , Vemuri, Prashanthi , Villemagne, Victor L. , Murray, Melissa E. , Rabinovici, Gil D. , DeCarli, Charles , Jack, Clifford R , Vemuri, Prashanthi , Miller, Bruce L , Murray, Melissa E , Masters, Colin L , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Seeley, William W. , Rowe, Christopher Cleon , Spina, Salvatore , Mclean, Catriona , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | October 20, 2018 | Volume: 15 | Issue: 2 | Pages: 205-216

10.1016/j.jalz.2018.09.001 | PMID 30347188 Get It

Abstract Introduction We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB‐PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ‐PET quantification. Methods Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET‐pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate‐to‐frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate‐to‐high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB‐PET study and established a range of pathology‐based CL thresholds.
Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences
Nickel, Brooke , Barratt, Alexandra , Brito, Juan P. , Moynihan, Ray , Howard, Kirsten , McCaffery, Kirsten , Brito, Juan P , McGeechan, Kevin

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 18, 2018 | Volume: 144 | Issue: 10 | Pages: 867

10.1001/jamaoto.2018.1272 | PMID 30335875 Get It

Intercepting Pancreatic Cancer
Lippman, Scott M. , Constantinou, Pamela E., Petersen, Gloria M. , Goggins, Michael , Jacks, Tyler , Syngal, Sapna , Maitra, Anirban

Mayo Clinic

Pancreas | October 16, 2018 | Volume: 47 | Issue: 10 | Pages: 1175-1176

10.1097/mpa.0000000000001165 | PMID 30325853 Get It

Immediate and Delayed Procedural Stroke or Death in Stenting Versus Endarterectomy for Symptomatic Carotid Stenosis
Müller, Mandy D. , Felten, Stefanie von , Becquemin, Jean‐Pierre , Brown, Martin M. , Bulbulia, Richard , Calvet, David, Fraedrich, Gustav , Hendrikse, Jeroen , Gregson, John , Howard, George , Jansen, Olav , Mas, Jean‐Louis , Brott, Thomas G. , Bonati, Leo H. , Howard, George , Algra, Ale , Eckstein, Hans‐Henning , Halliday, Alison , Ringleb, Peter Arthur

Mayo Clinic

Stroke | October 15, 2018 | Volume: 49 | Issue: 11 | Pages: 2715-2722

10.1161/strokeaha.118.020684 | PMID 30355202 Get It

Background and Purpose— Stenting for symptomatic carotid stenosis (carotid artery stenting [CAS]) carries a higher risk of procedural stroke or death than carotid endarterectomy (CEA). It is unclear whether this extra risk is present both on the day of procedure and within 1 to 30 days thereafter and whether clinical risk factors differ between these periods. Methods— We analyzed the risk of stroke or death occurring on the day of procedure (immediate procedural events) and within 1 to 30 days thereafter (delayed procedural events) in 4597 individual patients with symptomatic carotid stenosis who underwent CAS (n=2326) or CEA (n=2271) in 4 randomized trials. Results— Compared with CEA, patients treated with CAS were at greater risk for immediate procedural events (110 versus 42; 4.7% versus 1.9%; odds ratio, 2.6; 95% CI, 1.9–3.8) but not for delayed procedural events (59 versus 46; 2.5% versus 2.0%; odds ratio, 1.3; 95% CI, 0.9–1.9; interaction P =0.006). In patients treated with CAS, age increased the risk for both immediate and delayed events while qualifying event severity only increased the risk of delayed events. In patients treated with CEA, we found no risk factors for immediate events while a higher level of disability at baseline and known history of hypertension were associated with delayed procedural events. Conclusions— The increased procedural stroke or death risk associated with CAS compared with CEA was caused by an excess of events occurring on the day of procedure. This finding demonstrates the need to enhance the procedural safety of CAS by technical improvements of the procedure and increased operator skill. Higher age increased the risk for both immediate and delayed procedural events in CAS, mechanisms of which remain to be elucidated. Clinical Trial Registration— URL: https://clinicaltrials.gov . Unique identifier: NCT00190398. URL: http://www.isrctn.com . Unique identifier: ISRCTN57874028. URL: http://www.isrctn.com . Unique identifier: ISRCTN25337470. URL: https://clinicaltrials.gov . Unique identifier: NCT00004732.
Never Events in Radiology and Strategies to Reduce Preventable Serious Adverse Events
Ponce, Lisa , Osborn, Howard H., Jokerst, Clinton, Ponce, Lisa M, Flug, Jonathan A.

Mayo Clinic

RadioGraphics | October 10, 2018 | Volume: 38 | Issue: 6 | Pages: 1823-1832

10.1148/rg.2018180036 | PMID 30303781 Get It

Abstract TP137: Relationship Between Risk Factor Control and Physician Specialty in the CREST2 Trial
Voeks, Jenifer H. , Barrett, Kevin M. , Brown, Robert D. , Chimowitz, Marc I. , Emmady, Prabhu D. , Huston, John , Jones, Michael R. , Lal, Brajesh K. , Lazar, Ronald M. , Moore, Wesley S. , Moy, Claudia S., Roldan, Ana , Roubin, Gary S., Brott, Thomas G. , Turan, Tanya N. , Chaturvedi, Seemant , Demaerschalk, Bart M. , Howard, George , Howard, Virginia J. , Meschia, James F.

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.tp137 Get It

Background: In CREST2, intensive medical management of subjects’ vascular risk factors is overseen by the site Principal Investigator (PI) and implemented by a designated Medical Management Physician (MMP) and coordinator. These physicians have different specialties and experience with risk factor management. We sought to determine the relationship between risk factor control and PI and MMP specialty. Methods: Data on 613 patients with at least 1 follow-up visit from 105 CREST2 sites were used for these analyses. CREST2 sites were categorized based on both PI specialty and MMP specialty. Specialty of the site-designated primary MMP was used for sites with more than one MMP. We compared the percentage of patients in target at last follow-up visit for the primary risk factors, LDL < 70 mg/dL and SBP <140 mm Hg, among PI specialties and MMP specialties, using the chi-square test. Results: The table shows the number of patients by PI and MMP specialty, as well as their control of SBP and LDL. There were no significant differences in control of SBP or LDL by PI specialty. There was a trend toward an association between LDL control and MMP specialty, with higher rates of LDL control at sites with Internal Medicine MMP specialists and lower rates of control with Vascular Surgery MMPs. SBP control rates were not significantly different across MMP specialties. Conclusions: In this early analysis of risk factor control in the CREST2 study, site PI and MMP specialty did not have a significant effect on LDL and SBP during follow-up. This suggests that protocol care pathways are generalizable to diverse physicians.
Abstract TP135: Control of Vascular Risk Factors at Baseline in CREST-2
Barrett, Kevin M. , Roubin, Gary S., Heck, Donald , Jones, Michael R. , Wechsler, Lawrence R. , Rapp, Joseph H., Lal, Brajesh K. , Voeks, Jenifer H. , Brott, Thomas G. , Meschia, James F. , Turan, Tanya N. , Demaerschalk, Bart M. , Howard, George , Howard, Virginia J.

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.tp135 Get It

Rationale: Asymptomatic carotid stenosis is commonly seen in medical practice. CREST-2 is a pair of concurrent two-arm multi-site randomized trials of intensive medical management versus intensive medical management in combination with revascularization by endarterectomy or stenting. It is not known how often patients entering the trials have opportunities for further risk factor reduction at study entry and whether these opportunities vary across trial centers. Methods: Baseline data on 683 patients from 109 clinical sites were used for these analyses. We determined the rates of control at baseline for systolic blood pressure (SBP), defined as <140 mmHg (or ≥140 with >15mmHg orthostatic drop), and low density lipoprotein (LDL), defined as <70 mg/dl. We then tested differences in these baseline control rates by site-related characteristics, including site type, StrokeNet site vs. not, specialty of site Principal Investigator (PI), type of hospital, central vs local IRB, type of research team and whether site is enrolling in one or both trials. P-value <0.05 was considered significant. Results: At baseline, the mean SBP was 140.4±20.5 mmHg, but only 62% of participants were in target. The mean LDL at baseline was 83.7±36.9, mg/dl, with 42% in target. None of the site characteristics were associated with a higher level of control for SBP at baseline. The only characteristic associated with having a higher level of LDL control was sites enrolling in only the CAS trial (57%) compared to those enrolling in the CEA only (24%) or in both trials (42%) (p=0.02). Conclusions: Opportunities to improve on risk factors are common among CREST-2 participants, but site characteristics did not predict the likelihood of being at goal for SBP while sites enrolling in only the CAS trial had a higher level of LDL control.
Outcomes after carotid endarterectomy among elderly dual Medicare-Medicaid–eligible patients
Leifheit, Erica C , Wang, Yun , Howard, George , Howard, Virginia J. , Goldstein, Larry B. , Brott, Thomas G. , Lichtman, Judith H. , Howard, Virginia J , Howard, George

Mayo Clinic

Neurology | September 29, 2018 | Volume: 91 | Issue: 17 | Pages: No page available

10.1212/wnl.0000000000006380 | PMID 30266891 Get It

Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
Ljubenkov, Peter A. , Staffaroni, Adam M. , Allen, Isabel Elaine , Heuer, Hilary W. , Karydas, Anna, Kornak, John , Grinberg, Lea T. , Fagan, Anne M. , Jerome, Gina, Kramer, Joel H. , Miller, Bruce L. , Boxer, Adam L. , Rosen, Howard J. , Boeve, Brad F, Miller, Bruce L , Grinberg, Lea , Rojas, Julio C. , Wang, Ping , Cobigo, Yann , Seeley, William W. , Spina, Salvatore , Knopman, David S. , Boeve, Bradley F. , Dickerson, Bradford Clark

Mayo Clinic

Annals of Clinical and Translational Neurology | September 21, 2018 | Volume: 5 | Issue: 10 | Pages: 1250-1263

10.1002/acn3.643 | PMID 30349860 Get It

AbstractObjectiveThe prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau181, and amyloid beta1‐42was examined in frontotemporal dementia subtypes.MethodsWe compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits.ResultsNeurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau181predicted faster clinical progression whereas lower amyloid beta1‐42predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau181were of greater predictive value in patients with tau pathology as compared toTDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia.InterpretationHigh cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau181, and amyloid beta1‐42also predict some measures of disease aggressiveness in frontotemporal dementia.
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.
Boquimpani, Carla , Kim, Dong‐Wook , Benyamini, Noam , Clementino, Nelma Cristina D., Arias, Raquel De Paz, Moiraghi, Beatriz, Nicolini, Franck E., Dengler, Jolanta, Sacha, Tomasz , Takahashi, Naoto , Fellague-Chebra, Rafik, Acharya, Sandip, Wong, Stephane, Jin, Yu , Mahon, François‐Xavier , Hughes, Timothy P. , Shuvaev, Vasily , Ailawadhi, Sikander , Lipton, Jeffrey Howard , Turkina, Anna

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7054-7054

10.1200/jco.2016.34.15_suppl.7054 Get It